Clinical Trial Update: Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the PET radioligand BAY85-8102 F-18 (DPA-714) for neuroinflammation in probable Alzheimer's disease patients versus healthy volu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BAY85-8102 F-18 (DPA-714)
• DPA-714 (DPA-714 (a TSPO ligand))

Snippet

Sponsor: Bayer | Conditions: Diagnostic Imaging | Phase 1 | Status: COMPLETED